In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharm... ( WOODMERE N.Y. May 19 /- In an eleven...)

In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division

Date:5/19/2009

WOODMERE, N.Y., May 19 /PRNewswire/ -- In an eleventh-hour attempt to smear Ted Karkus, The Quigley Corporation (Nasdaq: QGLY) has issued a press release claiming that there was some improper financial arrangement between Dr. Richard Rosenbloom, a key staff member of a subsidiary of Quigley, and Mr. Ted Karkus, who leads a group of dissident shareholders who have offered their own slate of Quigley's Board of Directors for election at the annual meeting scheduled for Wednesday, May 20, 2009.

Mr. Karkus had loaned Dr. Rosenbloom a total of $55,000 over a period of approximately six months. The loans were sought by Dr. Rosenbloom for personal purposes. They are reflected in a written promissory note that provides, appropriately, for repayment of the loan and the payment of interest, and are secured by other assets of Dr. Rosenbloom.

Mr. Karkus did not seek, nor did he receive, any "inside information" in connection with the loan or otherwise.

Mr. Karkus has stated: "I am proud to have been in a position to help out someone in need. For the Company to attempt to manufacture a scandal on the last day of voting is disgraceful. It is quite obvious that they knew about this loan before today, and for the Company to treat Richard Rosenbloom so disgracefully is truly reprehensible."

Quigley has apparently determined to suspend, and perhaps discharge, Dr. Rosenbloom as a result of his alleged failure to report the loans to the CEO, Mr. Guy Quigley. Putting aside the question of what right Mr. Guy Quigley had to demand reports of this kind, the willingness of The Quigley Corporation to sacrifice Dr. Rosenbloom in an effort to impugn Mr. Karkus must be of grave concern to all shareholders. As the Company just stated in its Form 10-K, filed on March 9, 2009:

GOOD

1. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
2. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
3. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
4. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
5. Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion
6. GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform
7. BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management
8. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
9. Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity
10. US Oncology Provides Full Service Management of Clinical Trials
11. NexGen Biofuels Ltd Signs Letter of Intent for the Purchase of World Venture Management, Inc. Assets and the Sale of its Current Business

Post Your Comments:

In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharm...( WOODMERE N.Y. May 19 /- In an eleven...)